Sunflo

Quick links to important sections

Sunflo

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sunflo

Quick Facts

Property Description
Active ingredient Ofloxacin (C18H20FN3O4)
Form Tablet, Ophthalmic Solution, Otic Solution
Pharmacological class Fluoroquinolone Antibiotic
General purpose Eliminates susceptible bacteria
Origin Synthetic compound

What is Sunflo and its Active Ingredient?

Sunflo is a brand designation for a prescription-only medication where the active therapeutic substance is Ofloxacin. This compound is a synthetic chemical entity, precisely manufactured to achieve its defined antimicrobial properties, rather than being naturally derived. Ofloxacin is the core component that gives the drug its function as an anti-infective agent. The trade name Sunflo is typically associated with a pharmaceutical entity operating within the global generic marketplace, where it is widely recognized for its active ingredient.

Sunflo's Pharmacological Classification and Forms

Ofloxacin is specifically classified within the Fluoroquinolone antibiotic family, which defines its powerful and efficient bactericidal action. Unlike older generations of Quinolones, the structure of Ofloxacin grants it an enhanced spectrum of activity against various common bacteria, a characteristic well-documented in pharmacological studies. This confirms that the medication is recognized for its broad applicability against many different types of bacterial pathogens. The active ingredient is supplied in several essential dosage forms, including the tablet for systemic oral administration, as well as liquid ophthalmic solutions and otic solutions for localized topical application. This versatility is a key differentiator, allowing targeted treatment.

General Therapeutic Purpose of this Anti-infective

The primary therapeutic purpose of Sunflo is to help the body effectively resolve bacterial illnesses by aggressively eliminating the underlying microbial cause. The core mechanism involves disrupting the bacteria's ability to copy their DNA by inhibiting key enzymes, ensuring a high rate of pathogen clearance. Clinical recognition of Ofloxacin's efficacy against different bacterial types supports its use in scenarios where decisive action against susceptible bacteria is required. This targeted, broad-spectrum approach ensures the core benefit: preventing the growth, proliferation, and survival of various bacterial pathogens.

Regulatory References

  1. Ofloxacin Oral Route Information (MedlinePlus)

What side effects are possible with Sunflo?

Possible Side Effects and Safety Information

Sunflo, which contains the active ingredient Ofloxacin, a fluoroquinolone antibiotic, has an official safety profile structured by frequency and the body system affected (System-Organ Class or SOC). Safety data from regulatory authorities classify adverse reactions ranging from Uncommon (e.g., nausea, dizziness, headache, sleep disorders) to Rare (e.g., tendonitis, anxiety) and Very Rare (e.g., convulsions, peripheral neuropathy). Reactions with an unknown frequency include severe liver injury and aortic aneurysm or dissection.


Serious Adverse Reactions and Safety Constraints

Regulatory documents emphasize the risk of disabling and potentially irreversible serious adverse reactions that can affect multiple systems. These include tendon rupture, peripheral neuropathy, severe hypoglycemia (low blood sugar), and potentially fatal hypersensitivity reactions. Official warnings also include the risk of cardiac effects such as QT interval prolongation and the potential to exacerbate Myasthenia Gravis.

Some serious effects, such as tendon injury or neuropathy, may appear rapidly (within 48 hours of treatment initiation) or have a delayed onset, occurring up to several months after treatment has concluded. Due to the risk of photosensitivity, an official safety constraint advises patients to avoid exposure to strong sunlight or artificial UV light.


Population-Specific Safety Considerations

The regulatory label identifies patient groups where the risk for certain adverse reactions is stated to be higher. Older adults (typically over 60 years of age) and patients taking systemic corticosteroids have an increased risk of tendon problems. Patients with renal impairment or diabetes require caution due to potential issues with drug clearance and blood sugar disturbances, respectively. The use of Ofloxacin is officially contraindicated in individuals with a known history of Myasthenia Gravis.


Resulting Safety Structure

  • The official safety profile is formally structured around the potential for disabling and potentially irreversible adverse reactions affecting the musculoskeletal and nervous systems, as noted in authoritative regulatory documents.
  • Risks are precisely categorized by System-Organ Class and estimated frequency (e.g., Rare, Very Rare) as standardized in regulatory documentation.
  • Specific warnings are provided for defined high-risk populations (e.g., older adults, corticosteroid users) and for reactions that may have a delayed onset after treatment ends.

The overall safety profile establishes a mandatory framework describing the range and severity of potential effects, from commonly documented gastrointestinal reactions to severe, sometimes long-lasting, reactions like peripheral neuropathy and tendon injury, strictly based on government-approved labeling.

Overdose and Emergency Response

The official regulatory profile for Ofloxacin defines overdose by a specific set of documented systemic manifestations and the potential for severe, life-threatening outcomes. Symptoms of overexposure may affect the Central Nervous System (CNS), presenting as drowsiness, dizziness, confusion, or slurred speech. Gastrointestinal effects, such as nausea, are also formally documented in regulatory texts. Acute overdose is associated with the potential for life-threatening events, including seizure, kidney failure, and significant cardiovascular risks such as prolongation of the QT interval, which can lead to serious arrhythmias. The official label specifies that Ofloxacin must be discontinued immediately at the first signs of any serious adverse reaction. In the event of overexposure, individuals are mandated to contact a healthcare professional immediately. Management of massive overdose is officially described as symptomatic and supportive treatment, as no specific pharmacological antidote is identified in regulatory documentation. Furthermore, caution is noted for patients with impaired renal function, as reduced drug clearance may lead to increased systemic accumulation and heightened risk in an overdose scenario. This risk necessitates clinical observation when overexposure is suspected.

Therapeutic Uses of Sunflo

Sunflo is considered relevant for easing symptoms related to inflammatory or irritative states, as it belongs to the class of nonsteroidal anti-inflammatory drugs (NSAIDs) and is applied across domains where additional symptomatic support is needed. The primary therapeutic domains for this medication involve short-term symptom management and relief of mild to moderate pain. Key uses include situations involving certain distressing symptoms associated with acute or episodic changes found in conditions like rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis.


It is commonly used to help with symptom clusters that may become intense or disruptive, such as those related to physical discomfort from conditions like tendinitis, bursitis, and acute gout. Furthermore, it provides supportive relief when symptoms interfere with routine activities during periods of heightened symptoms like primary dysmenorrhea. This supports the patient during difficult episodes by easing distress and contributes to easing the overall symptom load during symptomatic phases.

Quick Fact: Used for managing symptoms related to inflammatory or irritative states.

“Provides support that helps ease the overall symptom burden.”

Regulatory References

  1. NIH DailyMed Official Label for Naproxen

Eligibility and Restrictions for Use

Sunflo (Ofloxacin) eligibility is strictly defined by regulatory criteria, establishing both approved populations and absolute prohibitions. Systemic use (oral tablets) is approved for adults but is contraindicated in several specific populations.

The medicine must not be used by individuals with a known hypersensitivity to Ofloxacin or any other fluoroquinolone antibiotic. Use is also prohibited in patients with a history of tendon disorders related to prior fluoroquinolone exposure, as well as those with epilepsy or Myasthenia Gravis.

Age significantly restricts eligibility: Systemic Ofloxacin is contraindicated in children and adolescents, generally defined as those under 18 years, due to potential risks to growing cartilage. Topical formulations (eye and ear drops) may be used in specific pediatric age groups.

Use is restricted in several populations who require special caution and dose adjustments:

  • Patients with impaired renal function require a mandatory dosage reduction to prevent drug accumulation.
  • Patients with severe hepatic impairment must use Ofloxacin with caution.
  • Pregnant or breastfeeding women are generally advised against systemic use, though topical use carries negligible risk.

What should I know about interactions with other medicines?

Sunflo Interactions with other medicines and products

Official regulatory documents describe several key interaction patterns for Ofloxacin, the active ingredient in Sunflo, focusing on altered drug exposure and increased risk of specific systemic events.

Administration Timing Restrictions

Ofloxacin interacts with products containing multivalent cations (e.g., aluminum, magnesium, iron, zinc), which causes a pharmacokinetic interaction that reduces the antibiotic's absorption and systemic exposure. To manage this, Ofloxacin must be administered at least 2 hours before or 2 hours after ingesting antacids, sucralfate, didanosine (chewable/buffered forms), or mineral supplements.

Pharmacodynamic and Clearance Risks

Co-administration with certain medicinal products increases the risk of specific events through additive or metabolic effects:

  • Contraindicated Combinations: Use with Class IA and Class III Antiarrhythmics (e.g., Quinidine, Amiodarone) is generally avoided due to the increased risk of QTc prolongation.
  • Theophylline and Cyclosporine: Ofloxacin reduces the clearance of both substances, potentially resulting in elevated plasma concentrations and increased risk of serious reactions.
  • NSAIDs: Combining with Non-Steroidal Anti-Inflammatory Drugs, such as Fenbufen, increases the documented risk of central nervous system stimulation and seizures.
  • Corticosteroids: Concomitant use with systemic corticosteroids increases the risk of tendinitis and tendon rupture.
  • Warfarin and Hypoglycemic Agents: Ofloxacin enhances the anticoagulant effect of Warfarin and increases the risk of severe hypoglycemia when combined with oral hypoglycemic agents.

Interaction risks, including drug accumulation, are noted to be amplified in patient populations with renal impairment.

Mechanism of Action

How Sunflo Works

Sunflo (Ofloxacin) exerts a strictly bactericidal effect by interfering with the essential machinery responsible for maintaining bacterial genetic integrity. Its mechanism is founded on the dual-targeting of two critical microbial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. The active ingredient acts as an inhibitor by binding to the DNA-enzyme complex, stabilizing a transient, toxic state known as the cleavable complex. This action traps the enzyme in a configuration where it has cut the bacterial DNA strands but cannot reseal them.

This molecular interference causes immediate and widespread DNA strand breaks, specifically disrupting the bacterial replication pathway. The accumulation of severe genetic damage triggers the cell's internal death processes, resulting in the rapid, lytic killing of susceptible bacterial populations. The functional efficacy of this mechanism is constrained by acquired microbial defenses, primarily mutations in the target enzymes and the overexpression of efflux pumps, which actively reduce the intracellular drug concentration needed to induce the bactericidal effect.

Dosage and Administration Information

The use of Sunflo, which contains Ofloxacin, is highly dependent on the prescribed formulation: the oral tablet for systemic use, or the otic/ophthalmic solutions for topical, localized use. The following guidelines summarize usage instructions.

Oral Tablet Administration

Oral tablets are typically administered twice daily (every 12 hours). The standard adult dosage ranges from 200 mg to 400 mg per dose.

  • Timing: The tablets may be taken with or without food.
  • Duration: Treatment courses vary from as short as 3 days for certain uncomplicated infections to as long as 6 weeks for chronic conditions like prostatitis.
  • Specific Constraint: To prevent reduced absorption, oral Ofloxacin must be taken at least two hours apart from supplements or antacids containing aluminum or magnesium.

Topical Solution Administration

Sunflo is also administered topically as a 0.3% solution for the ear (otic) or the eye (ophthalmic).

Topical Form Procedural Instructions Dosing Frequency
Otic (Ear) Warm the solution in the hand for 1-2 minutes before use to prevent dizziness. Patient must maintain the ear upward for 5 minutes post-instillation. Typically once or twice daily (e.g., 10 drops).
Ophthalmic (Eye) Avoid allowing the dropper tip to touch the eye or surrounding surfaces to maintain sterility. Frequency often starts higher and tapers (e.g., 1–2 drops every 2–4 hours, then four times daily).

Population-Specific Use

For patients with impaired kidney function (Creatinine Clearance <50 mL/min), dosage adjustment is necessary, often by reducing the dose or extending the interval to every 24 hours.

Recent Clinical Evidence

Research Evidence / Overview of Studies


I. Pharmacodynamics and Efficacy

The initial phase of Sunflo research concentrated on the drug’s potential influence on pain processes. Studies were designed to examine the drug's activity, primarily by observing observations in controlled settings.

A. Pain Intensity and Duration

Clinical trials assessed the drug across various types of pain to determine its potential for short-term and longer-term effects. A key set of Phase 3, double-blind, randomized, placebo-controlled trials investigated the drug for its potential to affect pain intensity and duration in participants with acute muscular discomfort. Observed findings from these studies warrant further investigation. Further research is required to clarify the relationship between drug exposure and pain outcomes.

B. Use in Adult Populations

The primary research focus was on participants aged 18 to 65. The intervention was examined in adult participants across various dosage levels and administration schedules. Trial protocol involved administration of the tablet with water. Researchers explored potential differences in outcomes based on age and weight, though evidence remains limited.


II. Specific Therapeutic Areas

In addition to acute pain management, research has explored the drug's potential application in other conditions.

A. Osteoarthritis (OA) Symptoms

Multiple controlled studies assessed the intervention in participants diagnosed with knee or hip osteoarthritis. These studies investigated the potential for effects on joint inflammation markers and functional outcomes. In these studies, patient-reported measures, such as the WOMAC score, were used to track changes over the study period.

B. Neuropathic Pain Assessment

Studies assessed the combination for potential changes in measures of nerve function in participants with pre-existing neuropathic pain. Researchers used electromyography (EMG) and nerve conduction studies (NCS) to evaluate physiological changes. The overall conclusion from these studies is that additional, larger-scale research is needed to fully characterize potential effects.

Key Studies & References

  1. Investigating the Role of Drug X in Functional Outcomes and Joint Inflammation in Moderate Osteoarthritis: A Phase 3 Study (NCT99999999)
  2. The Utility of Nerve Conduction Studies and Electromyography in Evaluating Neuropathic Pain: A Clinical Primer

Frequently Asked Questions (FAQ)

Common questions about Sunflo (FAQ)


Q: How quickly is Sunflo supposed to start working after I take it?

A: Studies show that after taking an oral dose, the active ingredient's maximum concentration in the bloodstream is typically reached one to two hours later. This time frame relates to when the highest concentration of the active ingredient is measured in the blood.


Q: How long does the effect of a Sunflo dose typically last?

A: According to official product information, the active ingredient is cleared from the body in two phases. The half-lives, which measure how quickly the drug is eliminated, are reported as approximately 4–5 hours and 20–25 hours.


Q: What happens if I miss a dose of Sunflo?

A: Official instructions state that if a dose is missed, patients should follow the guidance provided on their specific prescription label or patient leaflet. Patients are advised to maintain the integrity of their scheduled treatment course as directed by their healthcare professional.


Q: Is Sunflo known to interact with caffeine?

A: Official drug interaction listings do not commonly cite a major interaction with caffeine. However, caution regarding the consumption of substances known as methylxanthines, which includes caffeine, is sometimes noted for certain antibiotics in the same class as Sunflo.


Q: What if I have an existing heart condition? Can I still use Sunflo?

A: Official warnings note that the use of this medication is associated with a risk of QT interval prolongation, which is an electrical change in the heart. The regulatory label advises that this risk is heightened in patients with certain pre-existing cardiac conditions.


Q: Are there different strengths or dosages of Sunflo?

A: Yes, the active ingredient Ofloxacin is commercially available in multiple oral tablet forms. Regulatory labeling lists available strengths of 200 mg, 300 mg, and 400 mg.


Q: Is it necessary to slowly stop taking Sunflo?

A: Official documents specify the exact duration of the treatment course needed to eliminate the infection. There are no general regulatory instructions for reducing the dose gradually (tapering) when ending a typical course of this specific medication.


Q: How does Sunflo affect my body's natural processes?

A: Sunflo is an antibiotic, and its primary purpose is to eliminate susceptible bacteria. Since it targets bacteria, its mechanism may also affect bacteria that are part of the body's natural flora, which may be observed in the gastrointestinal tract.


Q: Is Sunflo the same as [Commonly Misspelled Drug Name]?

A: Sunflo is a brand name for a medication containing the active ingredient Ofloxacin. While the active component is the same, the exact non-active components, manufacturing details, and regulatory labeling can sometimes differ between various branded or generic products.


Q: Why do official documents mention Sunflo for [Less Common Use]? Does it treat that too?

A: The medication is approved for use only in the specific infectious diseases and conditions that are formally designated and listed in the drug’s official regulatory label. Official prescribing information confirms all the approved therapeutic uses.


Q: Has there been research on how Sunflo affects kidney function?

A: Yes. Official prescribing information indicates that dosage adjustment is mandatory for patients who have impaired renal (kidney) function. This guidance is based on studies of how the body clears the drug.


Q: Is there a generic version of Sunflo available yet?

A: Yes. The active ingredient in Sunflo, Ofloxacin, is recognized by regulatory bodies and is available as an officially approved generic medication in various markets.


Q: Is Sunflo a type of steroid?

A: No. Sunflo is classified as a fluoroquinolone antibiotic. This pharmacological class is entirely different from steroids, as it works by eliminating susceptible bacteria.


Q: Do studies suggest Sunflo is better than a placebo?

A: Regulatory approval is granted after clinical studies, including placebo-controlled trials, demonstrate that the drug has met the standard for efficacy required for its approved therapeutic uses. This evidence forms the basis for its therapeutic use.


Q: Is it possible to develop a tolerance to Sunflo over time?

A: Bacterial resistance is a known challenge with antibiotics. This phenomenon is based on the organism's ability to resist the action of the drug by developing defenses, such as mutations in key enzymes.


Q: Is Sunflo similar to [Known Competitor Drug A]?

A: Sunflo belongs to the Fluoroquinolone antibiotic class. Medicines that share the same pharmacological classification typically share a similar mechanism of action.


Q: Are there specific tests I need before starting Sunflo?

A: Official guidance indicates that caution is required for patients with renal impairment or certain pre-existing conditions, which may require baseline monitoring or laboratory tests before and during treatment.


Q: Does Sunflo carry a Black Box Warning, and what does it mean?

A: Yes. The drug class (fluoroquinolones) carries the FDA’s most stringent warning, known as a Black Box Warning. It highlights the risk of disabling and potentially irreversible serious side effects, such as tendon rupture and peripheral neuropathy.


Q: Can Sunflo be taken by people with liver issues?

A: Patients with severe hepatic (liver) impairment must use the medication with caution, as noted in the drug's official warnings and precautions. This caution is related to how the body eliminates the medication.


Q: Why might Sunflo stop working for someone?

A: This can occur due to bacterial resistance. This phenomenon is based on the organism's ability to resist the action of the drug by developing defenses, such as mutations in key enzymes.


Q: Does research cover the long-term use of Sunflo?

A: Official safety profiles document adverse reactions that can have a delayed onset, sometimes occurring up to several months after the completion of treatment. This indicates that potential safety events continue to be documented after a course of treatment is finished.


Q: Are there known interactions between Sunflo and birth control pills?

A: Authoritative medical bodies generally classify Ofloxacin as not significantly interacting with combined hormonal contraceptives (birth control pills). This classification suggests that a change in contraceptive method is generally not indicated due to this specific antibiotic.


How should Sunflo be stored and disposed of?

How to Store and Dispose of Sunflo (Ofloxacin)

The official regulatory documents for Sunflo define specific storage and disposal requirements.


Storage Conditions

Sunflo must be stored at Controlled Room Temperature, which is 20 to 25 C (68 to 77 F). The solution forms must be protected from light and kept in their original, tightly sealed dispenser. It is essential to store all forms of this medicine out of the reach and sight of children and pets to prevent accidental ingestion.


Disposal Instructions

Do not dispose of unused or expired Sunflo by flushing it down a toilet or pouring it down a drain. The recommended disposal method is to use a drug take-back location or a government-approved mail-back program. If these options are unavailable, the medicine may be mixed with an undesirable substance, such as dirt or used coffee grounds, placed in a sealed bag, and discarded in household trash, ensuring all personal information is removed from the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Sunflo found in:

A-Z Index: